72809-43-9

Upstream product

• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 89-98-5 2-chloro-benzaldehyde 
• 611-19-8 1-chloro-2-(chloromethyl)benzene 
• 611-17-6 1-bromomethyl-2-chlorobenzene 

Relevant academic research and scientific papers

Efficient synthesis of N-alkyl tetrahydroisoquinolines by reductive amination

An expedient access to diverse N-alkyl 1,2,3,4-tetrahydroisoquinolines is reported by reductive amination of aldehydes and ketones with tetrahydroisoquinoline (THIQ) in the presence of Ti(Oi-Pr)4 and NaBH4. The N-alkyl THIQ products

Diethyl Phosphite Promoted Electrochemical Oxidation of Tetrahydroisoquinolines to 3,4-Dihydroisoquinolin-1(2 H)-ones

A diethyl phosphite mediated electrochemical oxidation strategy for the synthesis of 3,4-dihydroisoquinolin-1(2 H)-ones from tetrahydroisoquinolines under mild conditions has been developed. This protocol provides an environmentally friendly and simple way for the construction of C=O bonds in an undivided cell unit.

Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites

The thienopyridine antiplatelet agent, ticlopidine and its analog, clopidogrel, have been shown to potentiate the action of β-lactam antibiotics, reversing the methicillin-resistance phenotype of methicillin-resistant Staphylococcus aureus (MRSA), in vitro. Interestingly, these thienopyridines inhibit the action of TarO, the first enzyme in the synthesis of wall teichoic acid, an important cell wall polymer in Gram-positive bacteria. In the human body, both ticlopidine and clopidogrel undergo a rapid P450-dependent oxidation into their respective antiplatelet-active metabolites, resulting in very low plasma concentrations of intact drug. Herein, a series of analogs of ticlopidine and clopidogrel that would avoid oxidative metabolism were designed, prepared and evaluated as inhibitors of TarO. Specifically, we replaced the P450-labile thiophene ring of ticlopidine and clopidogrel to a more stable phenyl group to generate 2-(2-chlorobenzyl)-1,2,3,4-tetrahydro- isoquinoline) (6) and (2-chloro-phenyl)-(3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid methyl ester (22), respectively. The latter molecules displayed inhibitory activity against TarO and formed the basis of a library of analogs. Most synthesized compounds exhibited comparable efficacy to ticlopidine and clopidogrel. So far, it was introduction of a trifluoromethyl group to compound 6, to generate 2-(2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-isoquinoline (13) that exhibited enhanced activity against TarO. Compound 13 represents a novel stable inhibitor of TarO with synergistic impact on β-lactam antibiotics against MRSA and low potential for P-450 metabolism.

Tetrahydro-isoquinoline derivatives

2-(2-Chlorobenzyl)-1,2,3,4-tetrahydroisoquinoline of the formula STR1 and its pharmaceutically acceptable addition salts, are useful for the treatment of arterial or venous thrombosis. They can be prepared by reducing the amide 2-(2-chlorobenzoyl)-1,2,3,4-tetrahydroisoquinoline, for example with boron hydride in an inert organic solvent, and optionally converting a free amine thereby produced into a salt.